Market Overview

UPDATE: Bank of America Upgrades Myriad Genetics to Buy on Diversification Strategy

Share:
Related MYGN
Benzinga Pro's 5 Stocks To Watch Today
Benzinga's Top Upgrades, Downgrades For March 21, 2018
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those ... (GuruFocus)

Bank of America raised its rating on Myriad Genetics (NASDAQ: MYGN) from Neutral to Buy and increased its price objective from $30 to $32.

Bank of America commented, "We upgrade MYGN shares to Buy from Neutral, as we are more positive on the company's efforts to diversify the business and expand its addressable markets, particularly as the company's flagship product, BRACAnalysis, matures. We think MYGN's strategy to increase its penetration in certain cancer indications while expanding overseas is viable, and are more optimistic on the ability to protect the BRACAnalysis franchise. We are also incrementally more positive on Prolaris and the pipeline, as well as the company's efforts in companion diagnostics."

Myriad Genetics closed at $25.37 on Tuesday.

Latest Ratings for MYGN

DateFirmActionFromTo
Mar 2018Morgan StanleyUpgradesUnderweightEqual-Weight
Feb 2018Leerink SwannMaintainsMarket PerformMarket Perform
Feb 2018Morgan StanleyMaintainsUnderweightUnderweight

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (MYGN)

View Comments and Join the Discussion!